The candidates merge two existing vaccines that have demonstrated favourable tolerability through randomised controlled ...
US FDA grants fast track designation to two Sanofi’s combination vaccine candidates to prevent influenza & Covid-19 infections: Paris Thursday, December 12, 2024, 10:00 Hrs [IST ...
The US Food and Drug Administration(FDA) has granted Fast Track designation to two non-mRNA combination vaccine candidates ...
A new review published in Blood Cancer Discovery outlines a major multiple myeloma research project that supported a key ...
The FDA bestows a Fast Track designation to Sanofi's two combination vaccine candidates to prevent influenza and COVID-19 infections.
Novavax NVAX announced that it has started dosing participants in the phase III study evaluating its experimental ...
The US Food and Drug Administration has granted Fast Track designation to two Sanofi combination vaccine candidates to prevent influenza and COVID-19 infections in individuals 50 years of age and ...
Paris: The US Food and Drug Administration (USFDA) has granted Fast Track designation to two Sanofi combination vaccine ...
The oral BTK inhibitor rilzabrutinib led to rapid and durable platelet responses, reduced bleeding, and improved fatigue in ...
ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITPPivotal phase 3 data ...
California-based biotech Nuvig Therapeutics scooped up $161 million from the investment arms of Sanofi, Bayer, Novo Holdings, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback